Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
| ▸ | CPA1 | P15085 | 1/20 | 0.30 |
| ▸ | CPB1 | P15086 | 1/20 | 0.30 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25636541 | 0.83 | CCR1 (0.41) | S1PR1S1PR3GABRA1GABRB2CPB2 | |
| SCHEMBL14754879 | 0.82 | NPC1 (0.43) | AOC3CYP11B1CYP11B2CHRM2CHRM3 | |
| SCHEMBL28956571 | 0.81 | AOC3 (0.39) | AOC3CYP11B1CYP11B2CHRM2CHRM3 | |
| SCHEMBL19245814 | 0.76 | CHRM2 (0.35) | AOC3CYP11B1CYP11B2CHRM2CHRM3 | |
| SCHEMBL19661516 | 0.73 | CHRM2 (0.33) | AOC3CYP11B1CYP11B2CHRM2CHRM3 | |
| SCHEMBL17297340 | 0.73 | CCR1 (0.61) | AOC3CHRM2CHRM3 | |
| SCHEMBL10130824 | 0.72 | KDM4E (0.48) | CYP11B1CYP11B2 | |
| SCHEMBL14762040 | 0.72 | AOC3 (0.37) | AOC3CYP11B1CHRM2CHRM3 | |
| Ammonia Solution, Strong SCHEMBL28956572 | 0.71 | CCR1 (0.59) | AOC3CHRM2CHRM3 | |
| SCHEMBL13429906 | 0.71 | CHRM2 (0.37) | AOC3CHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190134040-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190134040-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | S1PR1 1842/4885S1PR3 1805/4885AOC3 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.